TWD 126.5
(-1.94%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 469.27 Million TWD | 58559.0% |
2022 | 800 Thousand TWD | 0.0% |
2021 | - TWD | -100.0% |
2020 | 600 Thousand TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | - TWD | 0.0% |
2024 Q1 | - TWD | -100.0% |
2023 Q4 | 468.47 Million TWD | 58459.0% |
2023 FY | 469.27 Million TWD | 58559.0% |
2023 Q2 | - TWD | 0.0% |
2023 Q1 | - TWD | -100.0% |
2023 Q3 | 800 Thousand TWD | 0.0% |
2022 Q4 | 800 Thousand TWD | 0.0% |
2022 FY | 800 Thousand TWD | 0.0% |
2021 FY | - TWD | -100.0% |
2020 FY | 600 Thousand TWD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Allied Biotech Corporation | 720.43 Million TWD | 34.862% |
GeneFerm Biotechnology Co., Ltd. | 793.77 Million TWD | 40.881% |
Easywell Biomedicals, Inc. | 271.62 Million TWD | -72.763% |
TTY Biopharm Company Limited | 5.5 Billion TWD | 91.476% |
Synmosa Biopharma Corporation | 5.14 Billion TWD | 90.871% |
Orient EuroPharma Co., Ltd. | 4.59 Billion TWD | 89.78% |
Center Laboratories, Inc. | 1.39 Billion TWD | 66.336% |
Tien Liang BioTech Co., Ltd. | 459.99 Million TWD | -2.017% |
Orient Pharma Co., Ltd. | 889.91 Million TWD | 47.268% |
InnoPharmax Inc. | 46.07 Million TWD | -918.54% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 606.71 Million TWD | 22.653% |
Excelsior Biopharma Inc. | 771.56 Million TWD | 39.179% |
DV Biomed Co., Ltd. | 1.53 Billion TWD | 69.495% |
Foresee Pharmaceuticals Co., Ltd. | 195.03 Million TWD | -140.605% |
Handa Pharmaceuticals, Inc. | 1.1 Billion TWD | 57.583% |
UniPharma Co., Ltd. | 103.22 Million TWD | -354.624% |
Anxo Pharmaceutical Co., Ltd. | 939.94 Million TWD | 50.074% |
Winston Medical Supply Co., Ltd. | 709.07 Million TWD | 33.819% |
Mercury Biopharmaceutical Corporation | 1.03 Million TWD | -45328.074% |
Bioray Biotech Co., Ltd | 191.83 Million TWD | -144.629% |
TSH Biopharm Corporation Limited | 810.91 Million TWD | 42.131% |